5. The composition according to claim 1 wherein the amount of S-tofisopam or a prodrug, or pharmaceutically acceptable salt thereof is 99% or more by weight of the total weight of tofisopam.

Renumbered under Rule 1.126

Claim 6- ~~28~~ 27 (cancelled)

Claim ~~29~~ 28 (added)

~~29~~ 28. (Added) A composition according to claim 1, wherein the composition is for intraperitoneal, subcutaneous, intranasal, intramuscular, intrathecal, sublingual, rectal, intravenous infusion, transdermal delivery or oral administration.

Claim ~~30~~ 29 (added)

~~30~~ 29. (Added). A composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from approximately 10 mg to 1200 mg.

Claim ~~31~~ 30 (added)

~~31~~ 30. (Added) A composition according to claim 1, wherein the amount of S-tofisopam, prodrug or pharmaceutically acceptable salt thereof is from approximately 50 mg to 600 mg.

Claim ~~32~~ 31 (added)

31
~~32.~~ (Added) A composition according to claim 1, wherein the amount of S-tofisopam, prodrug or pharmaceutically acceptable salt thereof is from approximately 100 mg to 400 mg.

32
Claim ~~33~~ (added)

32
~~33.~~ (Added) A composition according to claim 1, wherein the amount of S-tofisopam, pro-drug or pharmaceutically acceptable salt administered is less than 30 mg/kg.